QMBlog Content
Discover More:
// December 08, 2023
Revisiting the Landscape of Potential Nitrosamines in Pharmaceuticals using CPCA fram...
Quality Matters recently sat down with USP Principal Scientist Naiffer Romero, who has teamed up with researchers at LHASA Limited, AstraZeneca, Sai Life Sciences and Merck for collaborative research on nitrosamine impurities. In Part One of this series, we discussed the new research. Here’s Part Two.
// November 27, 2023
Building a More Resilient Medicines Supply Chain
Building a More Resilient Medicines Supply Chain
In this Q&A with the Duke-Margolis Drug Supply Chain Resilience and Advanced Manufacturing Consortium, US Pharmacopeia (USP) policy expert Amy B. Cadwallader highlights the importance of multi-disciplinary, cross-functional coordination to strengthen the medicine supply chain and global public health resilience in the face of ongoing threats, like persistent drug shortages. This Q&A was first published in the Consortium's eNewsletter and is re-printed with the permission of the Duke-Margolis Center for Health Policy.
// November 27, 2023
Revisiting the Landscape of Potential Nitrosamines in Pharmaceuticals using CPCA fram...
USP’s Naiffer Romero has teamed up with researchers at LHASA Limited, AstraZeneca, Sai Life Sciences and Merck for collaborative research on nitrosamines impurities that was published this month in the Journal of Pharmaceutical Sciences. Quality Matters recently sat down with Romero, who leads USP’s Nitrosamines Exchange, to learn more about the new research and what it means for the field.
// October 24, 2023
Mitigating Cancer Drug Shortages: USP-American Cancer Society Summit Issues Call to A...
Patient access to cancer drugs can mean the difference between life and death. Persistent shortages threaten patients’ access to the lifesaving and life-sustaining therapies they need.
Show 6 More